Cannabinoid CB1 and CB2 receptor signaling and bias

Mikkel Søes Ibsen; Mark Connor; Michelle Glass

doi:10.1089/can.2016.0037

Cannabinoid CB₁ and CB₂ receptor signaling and bias

Mikkel Søes Ibsen, Mark Connor, Michelle Glass

Research output: Contribution to journal › Review article › peer-review

161 Citations (Scopus)

438 Downloads (Pure)

Abstract

An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB₁ and CB₂ each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB₁ and CB₂.

Original language	English
Pages (from-to)	48-60
Number of pages	13
Journal	Cannabis and Cannabinoid Research
Volume	2
Issue number	1
DOIs	https://doi.org/10.1089/can.2016.0037
Publication status	Published - 1 Mar 2017

Bibliographical note

Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

agonist bias
cannabinoid receptors
functional selectivity
G protein-coupled receptor

Access to Document

10.1089/can.2016.0037

Publisher version (open access)Final published version, 571 KBLicence: CC BY

Cite this

@article{8c258fbe92634bc49e7ffa6b258939dc,

title = "Cannabinoid CB1 and CB2 receptor signaling and bias",

abstract = "An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.",

keywords = "agonist bias, cannabinoid receptors, functional selectivity, G protein-coupled receptor",

author = "Ibsen, {Mikkel S{\o}es} and Mark Connor and Michelle Glass",

note = "Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2017",

month = mar,

day = "1",

doi = "10.1089/can.2016.0037",

language = "English",

volume = "2",

pages = "48--60",

journal = "Cannabis and Cannabinoid Research",

issn = "2378-8763",

publisher = "Mary Ann Liebert",

number = "1",

}

TY - JOUR

T1 - Cannabinoid CB1 and CB2 receptor signaling and bias

AU - Ibsen, Mikkel Søes

AU - Connor, Mark

AU - Glass, Michelle

N1 - Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.

AB - An agonist that acts through a single receptor can activate numerous signaling pathways. Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades. This concept, termed “biased signaling” represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades. The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways. This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.

KW - agonist bias

KW - cannabinoid receptors

KW - functional selectivity

KW - G protein-coupled receptor

U2 - 10.1089/can.2016.0037

DO - 10.1089/can.2016.0037

M3 - Review article

C2 - 28861504

SN - 2378-8763

VL - 2

SP - 48

EP - 60

JO - Cannabis and Cannabinoid Research

JF - Cannabis and Cannabinoid Research

IS - 1

ER -

Cannabinoid CB1 and CB2 receptor signaling and bias